• Publications
  • Influence
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands; Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris,
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Baseline gut microbiota enriched with Faecalibacterium and other Firmicutes is associated with beneficial clinical response to ipilimumab and more frequent occurrence of ipil optimumab-induced colitis.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Practical guidelines are proposed for the oncologist to help in the clinical care of patients under ICB immunotherapy, which can become life-threatening if not anticipated and managed appropriately.
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.
Angiosarcomas have an overall poor outcome, but with a clearly distinct prognosis depending on the primary site, and PS, liver and soft tissue tumors were identified as independent prognostic factors for progression-free survival.
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease and patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
It is demonstrated that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases
Tumor size was the only emerging prognosis factor in this retrospective study of 52 patients with CCS seen between April 1979 and April 2005 and emerged as a significant prognostic factor.
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.